Nicox Second Quarter 2018 Business - NASDAQ OMX GlobeNewswire

Nicox Second Quarter 2018 Business Update and Financial

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 17, 2018 at 1:45 AM 104

Nicox Second Quarter 2018 Business Update and Financial Highlights

Press Release
Nicox Second Quarter 2018 Business Update and Financial Highlights
.............................................. July 17, 2018 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided operational highlights and upcoming milestones, as well as revenues and cash position for Nicox and its subsidiaries (the "Nicox Group") as of June 30, 2018. Michele Garufi, Chairman and Chief Executive Officer of Nicox, stated, "VYZULTA sales by our global partner Bausch + Lomb grew substantially in the second quarter, reflected by an increase of over 180% in net royalty received by Nicox compared to the first quarter of 2018 . Looking ahead to the remainder of 2018, we expect to add a second revenue stream for the future through the planned launch in the fall of ZERVIATE(TM) in the United States by our U.S. partner Eyevance, and advancing towards the initiation of Phase 2 clinical studies for NCX 470 and NCX 4251." Key Upcoming Milestones · Q3 2018: Planned start of Phase 2 clinical study for NCX 470 for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. · Fall 2018: Expected commercial launch of ZERVIATE^TM (cetirizine ophthalmic solution), 0.24% in the United States by partner Eyevance Pharmaceuticals, LLC. · Q1 2019: Planned U.S. Investigational New Drug (IND) submission to the U.S. FDA for NCX 4251 to enable a Phase 2 clinical study in patients with acute exacerbations of blepharitis, following the successful, latest pre-IND meeting with the U.S. FDA in June 2018 (discussed below). Second Quarter 2018 and Recent Operational Highlights Research Collaboration with Ironwood Pharmaceuticals, Inc. In June 2018, we announced that we have entered into a research collaboration with Ironwood, focused on combining Ironwood's expertise in soluble guanylate cyclase (sGC) and our proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions. Further pre-IND meeting held for NCX 4251. In June 2018, an additional pre-IND meeting was held with the U.S. FDA, which addressed specific questions on development, including the potential primary endpoints for the Phase 2 clinical study. Based on the FDA comments from this and previous meetings, we are finalizing the design of the first in human Phase 2 clinical trial evaluating the safety and efficacy of NCX 4251 versus a vehicle comparator in subjects with acute exacerbations of blepharitis. We plan to submit an IND in Q1 2019 to enable this Phase 2 clinical study. Presentation of scientific data at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. In May 2018, we presented preclinical data on NCX 667, a lead molecule among our future generation stand-alone NO-donors, demonstrating the lowering of IOP in a robust, dose-dependent manner in various normotensive and hypertensive ocular models. Opening of new U.S. development office in Research Triangle Park, North Carolina. In April 2018, we announced our decision to relocate from our prior development office in Fort Worth, Texas, and to expand our presence in the United States to focus on the planned advancement of NCX 470 and NCX 4251 into Phase 2 clinical studies. Second Quarter 2018 Financial Highlights As of June 30, 2018, the Nicox Group had cash and cash equivalents of €32.6 million as compared with €36.3 million at March 31, 2018 and €41.4 million at December 31, 2017. Net revenue¹ for the second quarter of 2018 was €0.226 million, comprised exclusively of royalties on Q2 2018 sales of VYZULTA^TM by global partner Bausch + Lomb, after deduction of royalty payments due by Nicox. The Group recorded no revenues for the second quarter of 2017. Only the figure related to the cash position of the Group as of December 31, 2017 is audited; all other figures of this press release are non-audited. References Net revenue consists of revenue from collaborations less royalty payments which corresponds to Net profit in the consolidated statements of profit or loss
About Nicox
Nicox S.A. is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved U.S. New Drug Applications, VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIATE(TM) (cetirizine ophthalmic solution), 0.24%, licensed in the U.S. to Eyevance. In addition, our promising pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a future generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com .
Analyst coverage
Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Jamina EL Bougrini Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Upcoming financial and business conferences

September 19 Goodwin, Solebury Trout European and Nasdaq European Biotech Investor Day New York, USA September 25-26 Oppenheimer Fall Summit New York, USA October 1-3 Cantor Global Healthcare Conference New York, USA November 22-23 Bryan, Garnier 6^th Annual Healthcare Conference Paris, France

Contacts
Nicox Gavin Spencer, Executive Vice President, Chief Business Officer T +33 (0)4 97 24 53 00 communications@nicox.com
Investor Relations Europe Nicox Corporate Communications Department T +33 (0)4 97 24 53 00 communications@nicox.com	Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 jonathan.birt@ymail.com
United States Argot Partners Melissa Forst T +1 (212) 600-1902 melissa@argotpartners.com	France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 nicox@newcap.eu
	United States Argot Partners David Rosen T +1 (212) 600-1902 david.rosen@argotpartners.com Italy Argon Healthcare International Pietro Pierangeli pietro.pierangeli@argonhealthcare.com Chiara Tettamanti chiara.tettamanti@argonhealthcare.com T. +39 02 4951.8300
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the ' Document de référence, rapport financier annuel et rapport de gestion 2017 ' filed with the French Autorité des Marchés Financiers (AMF) on March 19, 2018, which is available on Nicox's website (www.nicox.com).
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99

Attachment

Press release.pdf

Newer

Older

Top 10 Most Recent News Articles

Fast Guard Elevates Nationwide Fire Watch Mission

Fast Guard: The Unseen Shield Behind Property Safety Hollywood, Florida might be best known for its sun-kissed beaches, but in the world of fire safety, it’s the nerve center for emergency fire watch response. Fast Guard Service isn’t just any run-of-the-mill security outfit; it’s rapidly becoming the unsung hero of property managers across the nation. When those...

GAC's Cambodia Plant: A Strategic Manufacturing Shift

Setting the Stage for New Industrial Growth On September 17, a milestone was etched in the sands of Cambodia when the GAC Cambodia KD Plant officially flipped the switch. This ain't just another factory throwing doors open; it's a fresh chapter in regional manufacturing power plays. We had some big hitters in attendance, like Cambodian Prime Minister Hun Manet, showing...

Why Liver Nurture Taps into Health Sector Trends

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

China's Tech Success Echoes in Global Living Rooms

A New Player in Global Tech If you've been sleeping on China's tech scene, it's time to wake up. Moonshot AI just launched Kimi K3, the largest open-source model by parameters we've seen, a significant leap in artificial intelligence that's catching even the eyes of folks who hardly touch technology—like retirees in Italy. Rapid AI Advancements China's story isn't about...

Med Spa Visits: Key Insights from Lindsey Smith

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...

Chery Auto's Bold Green Tech Showcase at 2026 Summit

Chery Auto Puts Eco Tech at Front and Center You know, Chery Auto isn't just manufacturing cars anymore—it's shaping an entire lifestyle. For the uninitiated, they’re calling in everyone worth knowing to their headquarters in Wuhu, China, come October 18 through 24. The 2026 Chery International User Summit is kind of a big deal this year with nearly 20 new green...

Papa John's Faces Class Action Over Misleading Info

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Insta360 Expands with Times Square Flagship Store

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

USPS Rolls Out Christmas Cookie Stamps Nationwide

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Hainan Airlines' Dedication Keeps It atop Skytrax

Fifteen years of soaring high: now that's something worth taking to the bank—or the air. Hainan Airlines has just bagged the SKYTRAX Five-Star Airline rating once again, handed out at this year's World Airline Awards ceremony. When it comes to delivering quality, they're flying high on the charts, landing among the World's Best Airlines Top 10. And in the wild world of...